Recommended

FDA tightens COVID vaccine use
Decentralised manufacturing consortium launched
Trial boost for myasthenia gravis drug
FDA starts publishing daily AE data
WEBINAR | The Future of Sterility Testing: One-Day Results with Advanced RT-rt PCR Technology | 5 NOV
WEBINAR | Mastering Impurity Profiling: USP’s Evolving Standards and Strategies | 15 OCT
news

Finnish manufacturing facility to get €50m expansion

0
SHARES

The planned €50 million investment at the Finland-based CDMO facility will enable advanced technologies to be used for development and manufacture of advanced therapy medicinal products (ATMPs).

Biovian Finnish manufacturing facility to get €50m expansion

Credit: Biovian

A Finnish contract development and manufacturing organisation (CDMO) specialising in biopharmaceuticals, has announced it is investing over €50 million to expand its manufacturing facility in Turku, Finland. Biovian’s financing will help to meet the growing demand for innovative biologics and gene therapies. 

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

Antti Nieminen, CEO of Biovian, stated that the new manufacturing facility will “contribute to the growth of the biopharmaceutical industry in Finland”.

The size of the new facility will be 6,400m2 (69,000ft2). Cutting-edge equipment and advanced technologies will support the development, manufacturing, and testing of advanced therapy medicinal products (ATMPs). These include adenoviral and adeno-associated viral therapies (AAVs). The site will also feature dedicated Class A to D cleanroom areas for bulk drug substances as well as final drug product manufacture.

The evolution of AAVs in cell and gene therapy

Biovian’s new space adds to the company’s existing manufacturing facilities in the area. Ultimately, the addition will enable the CDMO to undertake larger-scale viral vector as well as microbial protein projects and concurrent manufacturing campaigns, by increasing overall production capacity and flexibility.

According to the contract development and manufacturing organisation’s CEO, the expanded facility “will increase viral vector capacity, but it will also increase our capacity and flexibility in microbial protein. When the new site is up and running, our existing capacity will be transformed to new microbial protein suites.”

The investment is expected to create 100 jobs in the region. This opportunity will add to the team, which currently has approximately 200 employees.

The project is expected to be completed in December 2024. The new facility is expected to be fully operational by 2025.

The cell and gene therapy CDMO bottleneck isn’t capacity – it’s capability

Share via
Share via